43200-31-3

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 98-09-9 benzenesulfonyl chloride 
• 88-74-4 2-nitro-aniline 
• 93-98-1 N-phenyl benzoyl amide 
• 89-63-4 4-Chloro-2-nitroaniline 
• 6933-51-3 N-(2-nitrophenyl)benzenesulfonamide 

Downstream Products

• 69627-35-6 N,N'-bis(benzenesulfonyl)-o-phenylenediamide 
• 1417532-71-8 C₂₁H₂₀N₂O₂S 
• 1417532-72-9 C₂₂H₂₂N₂O₂S 
• 1417539-51-5 C₂₄H₂₂N₄O₄PdS₂ 
• 15728-50-4 2-phenyl-1-(phenylsulfonyl)-1H-benzo[d]imidazole 
• 215917-77-4 N-[2-(3-phenylureido)phenyl]benzene-sulfonamide 
• 1346812-17-6 1-phenylsulfonyl-1,3-dihydro-2H-benzimidazole-2-thione 
• 209685-43-8 methyl 4-[({5-chloro-2-[(phenylsulfonyl)amino]phenyl}amino)carbonyl]benzoate 
• 4106-18-7 1-(phenylsulfonyl)-1H-benzo[d][1,2,3]triazole 

Relevant academic research and scientific papers

Palladium(II) complexes assembled on solid materials: as catalysts for the –NO2 (nitro) to –NH2 (amine) reactions

Abstract: Herein, a new series of [PdCl2(L)2] complexes where ligands are monodentate amine ligands bearing sulfonamide groups were synthesized, characterized using various techniques such as NMR, FT-IR, UV–Vis, and sc-XRD and invest

Synthesis of Structurally Diverse Benzotriazoles via Rapid Diazotization and Intramolecular Cyclization of 1,2-Aryldiamines

An operationally simple method has been developed for the preparation of N-unsubstituted benzotriazoles by diazotization and intramolecular cyclization of a wide range of 1,2-aryldiamines under mild conditions, using a polymer-supported nitrite reagent and p-tosic acid. The functional group tolerance of this approach was further demonstrated with effective activation and cyclization of N-alkyl, -aryl, and -acyl ortho-aminoanilines leading to the synthesis of N1-substituted benzotriazoles. The synthetic utility of this one-pot heterocyclization process was exemplified with the preparation of a number of biologically and medicinally important benzotriazole scaffolds, including an α-amino acid analogue.

One-pot stepwise reductive amination reaction by N-coordinate sulfonamido-functionalized Ru(II) complexes in water

New complexes of formula [RuCl(p-cymene)(L)] (7–12) were prepared with [RuCl2(p-cymene)]2 and pre-synthesized N-arenesulfonly-o-phenylenediamines (1–6) and characterized using 1H NMR, 13C NMR, Fourier transform

METHODS OF INHIBITING BACTERIAL VIRULENCE AND COMPOUNDS RELATING THERETO

The present invention relates to compounds and methods for the treatment of bacterial infections. Because their mechanism of action does not involve killing of bacteria or inhibiting their growth, the potential for these compounds to induce drug resistance in bacteria is minimized. Through inhibiting bacterial virulence, the present invention provides a novel means of treating bacterial infections.

RECORDING MATERIAL PRODUCED USING NON-PHENOL COMPOUND

An object of the present invention is to provide a recording material or a recording sheet using, as a color-developing agent, a non-phenol compound that is a safe compound in no danger of corresponding to an endocrine disruptor and is good in color devel

Synthesis, characterization and catalytic properties of novel palladium(II) complexes containing aromatic sulfonamides: Effective catalysts for the oxidation of benzyl alcohol

In this article, N-(2-aminophenyl)arylsulfonamides (1-5) were successfully synthesized by the reaction of o-phenylenediamine and various benzenesulfonyl chlorides. The Schiff base derivatives (1a-f; 4e) of those compounds were obtained using different ald

Discovery of new chemical leads for selective EP1 receptor antagonists

A series of 4-({2-[alkyl(phenylsulfonyl)amino]phenoxy}methyl)benzoic acids were identified as functional PGE2 antagonists with selectivity for the EP1 receptor subtype starting from a chemical lead 1, which was found while screening our in-house compound library. Discovery of the optimized analogs 21-23 is presented here and structure-activity relationships (SAR) are also discussed.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.